NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell

Key Points

• Zacks Research downgraded NRx Pharmaceuticals to “Strong Sell” from “Hold,” although analyst sentiment remains mixed: five analysts rate the stock Buy and two rate it Sell, producing a consensus Hold rating and a $34.50 price target.
• NRx reported a quarterly loss of $0.44 per share, missing the $0.11 consensus estimate, while revenue of $1.10 million also fell short of the $1.33 million forecast.
• Shares opened at $3.62, with a market capitalization of approximately $156.75 million. The company’s stock has traded between $1.62 and $5.05 over the past year, and institutional investors own just 4.27% of shares.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued on Wednesday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. D. Boral Capital reaffirmed a "buy" rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. HC Wainwright restated a "buy" rating on shares of NRx Pharmaceuticals in a research report on Tuesday. UBS Group reaffirmed a "buy" rating on shares of NRx Pharmaceuticals in a report on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, BTIG Research reissued a "buy" rating and issued a $10.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP opened at $3.62 on Wednesday. The business's fifty day moving average price is $3.72 and its two-hundred day moving average price is $3.05. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The stock has a market capitalization of $156.75 million, a price-to-earnings ratio of -6.58 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its quarterly earnings data on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. Research analysts expect that NRx Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds have recently modified their holdings of NRXP. Geode Capital Management LLC increased its holdings in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Vanguard Group Inc. raised its position in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock worth $1,765,000 after purchasing an additional 82,781 shares during the last quarter. Two Sigma Investments LP lifted its holdings in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after buying an additional 20,880 shares in the last quarter. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals during the 4th quarter worth $107,000. Finally, Bleakley Financial Group LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at $318,000. 4.27% of the stock is owned by institutional investors.

Key NRx Pharmaceuticals News

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on NRx Pharmaceuticals, signaling continued confidence in the company’s longer-term prospects despite weaker near-term estimates. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
• Neutral Sentiment: HC Wainwright still forecasts a potential transition to profitability, with estimated EPS of $0.15 in fiscal 2028, $0.71 in 2029 and $1.14 in 2030. However, those projections remain highly dependent on successful execution and future revenue growth.
• Negative Sentiment: The analyst cut projected EPS for the third and fourth quarters of 2026 to losses of $0.43 and $0.50, respectively, from previous estimates of losses of $0.06 and $0.07. Forecasts for the first three quarters of 2027 were also reduced to losses of $0.30, $0.15 and $0.05 per share.
• Negative Sentiment: Full-year earnings estimates were sharply lowered: 2027 moved to a $0.50-per-share loss from a $0.67 profit, while estimates for 2028, 2029 and 2030 fell to $0.15, $0.71 and $1.14 from $2.49, $4.51 and $5.76, respectively. These revisions imply slower commercialization or weaker financial performance than previously expected.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source